IconOVir
  • About Us
    • Meet our Team
    • Board of Directors
    • Scientific Advisory Board
  • News/Events
    • Press Releases
  • Careers
  • Contact
Menu
  • About Us
    • Meet our Team
    • Board of Directors
    • Scientific Advisory Board
  • News/Events
    • Press Releases
  • Careers
  • Contact

Press Releases

  • June 23, 2022

IconOVir Bio Appoints William Kaelin, Jr., M.D., to Board of Directors

  • June 6, 2022

IconOVir Bio Appoints John Huynh, Ph.D., as Chief Technology Officer

  • June 3, 2022

IconOVir Bio to Present at Jefferies Healthcare Conference

  • May 18, 2022

IconOVir Bio to Present at UBS Global Healthcare Conference

  • May 27, 2021

IconOVir Bio to Present at Jefferies Healthcare Conference

  • May 20, 2021

IconOVir Bio Announces Preclinical Proof-of-Concept Data for Proprietary Mutations Designed to Improve Selectivity of Novel Oncolytic Viruses, Including Lead Product Candidate ICVB-1042

  • April 20, 2021

IconOVir Bio Announces Formation of Scientific Advisory Board

  • January 5, 2021

IconOVir Bio Raises $77 Million in Series A Financing to Develop Next-Generation Oncolytic Viruses to Treat Solid Tumors

CORPORATE OFFICE

IconOVir Bio
4570 Executive Drive
Suite 350
San Diego, CA 92121

 

Partnering Inquiries
info@iconovir.com
MEDIA INQUIRIES AT
media@iconovir.com
Linkedin
Contact Us
CORPORATE OFFICE

IconOVir Bio
4570 Executive Drive
Suite 350
San Diego, CA 92121

 

Partnering Inquiries
info@iconovir.com
MEDIA INQUIRIES AT
media@iconovir.com
Linkedin
Contact Us
CORPORATE OFFICE

IconOVir Bio
4570 Executive Drive
Suite 350
San Diego, CA 92121

 

Partnering Inquiries
info@iconovir.com
MEDIA INQUIRIES AT
media@iconovir.com
Linkedin
Contact Us
©2021 IconOVir Bio
©2021 IconOVir Bio